Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + decitabine/azacitidine + aclarubicin for relapsed or refractory acute myeloid leukemia
ChiCTR2400088404Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, decitabine, azacitidine and aclarubicin in acute myeloid leukemia (AML), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Composite complete remission rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
venetoclaxdecitabineazacitidineaclarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400088404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088404.